Login to Your Account



Big bounce for Jounce: Firm lands $2.56B Celgene immuno-oncology collaboration

By Michael Fitzhugh
Staff Writer

Tuesday, July 19, 2016

Jounce Therapeutics Inc. will receive a $225 million up-front payment and a $36 million equity investment as part of a five-candidate immuno-oncology (I-O) collaboration with Celgene Corp.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription